HM Payson & Co. Sells 102 Shares of Becton, Dickinson and Company (BDX)

HM Payson & Co. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,192 shares of the medical instruments supplier’s stock after selling 102 shares during the period. HM Payson & Co.’s holdings in Becton, Dickinson and were worth $14,476,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America boosted its position in shares of Becton, Dickinson and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC boosted its position in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after purchasing an additional 7 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares during the last quarter. Northstar Group Inc. boosted its position in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after purchasing an additional 9 shares during the last quarter. Finally, Smithfield Trust Co. boosted its position in shares of Becton, Dickinson and by 0.3% in the 2nd quarter. Smithfield Trust Co. now owns 7,693 shares of the medical instruments supplier’s stock worth $1,501,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “HM Payson & Co. Sells 102 Shares of Becton, Dickinson and Company (BDX)” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/20/hm-payson-co-sells-102-shares-of-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 193.00 on Wednesday. The firm has a 50 day moving average price of $199.01 and a 200 day moving average price of $191.58. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The firm has a market cap of $43.92 billion, a P/E ratio of 55.89 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.35 EPS. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock worth $15,242,688 in the last three months. Insiders own 1.40% of the company’s stock.

Several research analysts have recently issued reports on BDX shares. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Cowen and Company reiterated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 17th. Finally, Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and a consensus target price of $196.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply